Targeting interferons in multiple sclerosis

Yuji Nakatsuji; Masayuki Moriya; Saburo Sakoda

doi:10.1016/j.ddstr.2007.08.004

Targeting interferons in multiple sclerosis

Yuji Nakatsuji^*, Masayuki Moriya, Saburo Sakoda

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Since interferon (IFN)-β was first approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in 1993 in the United States, the indication expanded to secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS). Supported by the evidence of efficacy derived from many clinical trials, IFN-β became an established agent. In this review, we summarize current knowledge about the putative mechanism of therapeutic effects of IFN-β and pivotal trials so far performed and discuss directions of MS therapy.

Original language	English
Pages (from-to)	49-55
Number of pages	7
Journal	Drug Discovery Today: Therapeutic Strategies
Volume	4
Issue number	1
DOIs	https://doi.org/10.1016/j.ddstr.2007.08.004
State	Published - 2007

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.1016/j.ddstr.2007.08.004

Cite this

@article{6a803c69f17f48b7889114cfd890c943,

title = "Targeting interferons in multiple sclerosis",

abstract = "Since interferon (IFN)-β was first approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in 1993 in the United States, the indication expanded to secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS). Supported by the evidence of efficacy derived from many clinical trials, IFN-β became an established agent. In this review, we summarize current knowledge about the putative mechanism of therapeutic effects of IFN-β and pivotal trials so far performed and discuss directions of MS therapy.",

author = "Yuji Nakatsuji and Masayuki Moriya and Saburo Sakoda",

year = "2007",

doi = "10.1016/j.ddstr.2007.08.004",

language = "英語",

volume = "4",

pages = "49--55",

journal = "Drug Discovery Today: Therapeutic Strategies",

issn = "1740-6773",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - Targeting interferons in multiple sclerosis

AU - Nakatsuji, Yuji

AU - Moriya, Masayuki

AU - Sakoda, Saburo

PY - 2007

Y1 - 2007

N2 - Since interferon (IFN)-β was first approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in 1993 in the United States, the indication expanded to secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS). Supported by the evidence of efficacy derived from many clinical trials, IFN-β became an established agent. In this review, we summarize current knowledge about the putative mechanism of therapeutic effects of IFN-β and pivotal trials so far performed and discuss directions of MS therapy.

AB - Since interferon (IFN)-β was first approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in 1993 in the United States, the indication expanded to secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS). Supported by the evidence of efficacy derived from many clinical trials, IFN-β became an established agent. In this review, we summarize current knowledge about the putative mechanism of therapeutic effects of IFN-β and pivotal trials so far performed and discuss directions of MS therapy.

UR - http://www.scopus.com/inward/record.url?scp=37349041500&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2007.08.004

DO - 10.1016/j.ddstr.2007.08.004

M3 - 総説

AN - SCOPUS:37349041500

SN - 1740-6773

VL - 4

SP - 49

EP - 55

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

IS - 1

ER -

Targeting interferons in multiple sclerosis

Abstract

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this